Jaishree Garhyan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jaishree Garhyan has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Chieh-Wen Lo
Department of Medicine, Stanford University, Stanford, CA 94305, USA
2 shared publications- Marwah Karim
Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
2 shared publications Aimee Beck
Department of Medicine, Stanford University, Stanford, CA 94305, USA
1 shared publication- Aleksandra Drelich
Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA
1 shared publication Amol Arunrao Pohane
Stanford In Vitro Biosafety Level 3 Service Center, Stanford University, Stanford, CA, USA
1 shared publication- Arjun Rustagi
Department of Medicine, University of California, San Francisco, San Francisco, USA
1 shared publication
Latest Publications
- Open Access
- 17 April 2026
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 5 (5)
Cell factories that manufacture microvesicles containing gene silencing RNA prodrugs
Among the vehicles investigated as delivery agents for antisense RNAs are extracellular vesicles (EVs) released from cultured cells. Arrestin domain–containing 1 (ARRDC1)-mediated microvesicles (ARMMs) are naturally occurring EVs that uniquely are formed by outward budding of cytoplasmic membranes. Previous work has shown that ARMMs production is quantitatively controlled by the ARRDC1 protein and that ARRDC1 and macromolecules attached to it are loaded into nascent ARMMs during ARMM formation. Here, we report a strategy for constructing cell factories that biologically manufacture both ARMMs and short hairpin RNA (shRNA)-like antisense RNA precursors, designated as shT-RNAs. Human HEK293T cells mutated in the endoribonuclease DICER1 were engineered to express a fusion protein containing components of ARRDC1 and the trans-activator of transcription (Tat) peptide encoded by the HIV-1 virus. Prodrug RNAs were constructed by replacing the canonical loop regions of shRNAs with a 24-nucleotide segment derived from the Tat-binding trans-activation response (TAR) element. We show that a truncated TAR sequence embedded within the structural framework of shT-RNAs enables their linkage to the ARRDC1–Tat fusion protein and consequent loading of the RNAs into nascent ARMMs, and that RNA is protected by ARMMs membranes from attack by external ribonucleases. We further show that prodrug modules consisting of shT-RNAs that target different genomic sequences of SARS-CoV-2 virus and are manufactured as components of a single transcript can, when delivered by ARMMs, be activated to suppress virus RNA production. Our results indicate that the ARMMs-based platform we have designed can deliver gene-silencing RNAs in the form of biologically produced shRNA-like prodrugs.
- 17 April 2026
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 5 (5)
Open AccessCell factories that manufacture microvesicles containing gene silencing RNA prodrugs
Among the vehicles investigated as delivery agents for antisense RNAs are extracellular vesicles (EVs) released from cultured cells. Arrestin domain–containing 1 (ARRDC1)-mediated microvesicles (ARMMs) are naturally occurring EVs that uniquely are formed by outward budding of cytoplasmic membranes. Previous work has shown that ARMMs production is quantitatively controlled by the ARRDC1 protein and that ARRDC1 and macromolecules attached to it are loaded into nascent ARMMs during ARMM formation. Here, we report a strategy for constructing cell factories that biologically manufacture both ARMMs and short hairpin RNA (shRNA)-like antisense RNA precursors, designated as shT-RNAs. Human HEK293T cells mutated in the endoribonuclease DICER1 were engineered to express a fusion protein containing components of ARRDC1 and the trans-activator of transcription (Tat) peptide encoded by the HIV-1 virus. Prodrug RNAs were constructed by replacing the canonical loop regions of shRNAs with a 24-nucleotide segment derived from the Tat-binding trans-activation response (TAR) element. We show that a truncated TAR sequence embedded within the structural framework of shT-RNAs enables their linkage to the ARRDC1–Tat fusion protein and consequent loading of the RNAs into nascent ARMMs, and that RNA is protected by ARMMs membranes from attack by external ribonucleases. We further show that prodrug modules consisting of shT-RNAs that target different genomic sequences of SARS-CoV-2 virus and are manufactured as components of a single transcript can, when delivered by ARMMs, be activated to suppress virus RNA production. Our results indicate that the ARMMs-based platform we have designed can deliver gene-silencing RNAs in the form of biologically produced shRNA-like prodrugs.
- 13 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (738) , eadi0979
An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations
Inhibitors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M pro ) such as nirmatrelvir (NTV) and ensitrelvir (ETV) have proven effective in reducing the severity of COVID-19, but the presence of resistance-conferring mutations in sequenced viral genomes raises concerns about future drug resistance. Second-generation oral drugs that retain function against these mutants are thus urgently needed. We hypothesized that the covalent hepatitis C virus protease inhibitor boceprevir (BPV) could serve as the basis for orally bioavailable drugs that inhibit SARS-CoV-2 M pro more efficiently than existing drugs. Performing structure-guided modifications of BPV, we developed a picomolar-affinity inhibitor, ML2006a4, with antiviral activity, oral pharmacokinetics, and therapeutic efficacy similar or superior to those of NTV. A crucial feature of ML2006a4 is a derivatization of the ketoamide reactive group that improves cell permeability and oral bioavailability. Last, ML2006a4 was found to be less sensitive to several mutations that cause resistance to NTV or ETV and occur in the natural SARS-CoV-2 population. Thus, anticipatory design can preemptively address potential resistance mechanisms to expand future treatment options against coronavirus variants.
- 13 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (738) , eadi0979
An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations
Inhibitors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M pro ) such as nirmatrelvir (NTV) and ensitrelvir (ETV) have proven effective in reducing the severity of COVID-19, but the presence of resistance-conferring mutations in sequenced viral genomes raises concerns about future drug resistance. Second-generation oral drugs that retain function against these mutants are thus urgently needed. We hypothesized that the covalent hepatitis C virus protease inhibitor boceprevir (BPV) could serve as the basis for orally bioavailable drugs that inhibit SARS-CoV-2 M pro more efficiently than existing drugs. Performing structure-guided modifications of BPV, we developed a picomolar-affinity inhibitor, ML2006a4, with antiviral activity, oral pharmacokinetics, and therapeutic efficacy similar or superior to those of NTV. A crucial feature of ML2006a4 is a derivatization of the ketoamide reactive group that improves cell permeability and oral bioavailability. Last, ML2006a4 was found to be less sensitive to several mutations that cause resistance to NTV or ETV and occur in the natural SARS-CoV-2 population. Thus, anticipatory design can preemptively address potential resistance mechanisms to expand future treatment options against coronavirus variants.
- Open Access
- 23 February 2024
- Published by Elsevier in STAR Protocols
- Vol. 5 (1) , 102906
Chemical inactivation strategies for SARS-CoV-2-infected cells and organoids
- 23 February 2024
- Published by Elsevier in STAR Protocols
- Vol. 5 (1) , 102906
Open AccessChemical inactivation strategies for SARS-CoV-2-infected cells and organoids